Followers | 9 |
Posts | 750 |
Boards Moderated | 0 |
Alias Born | 10/19/2008 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, November 02, 2009 9:16:12 AM
It is also nice to understand your thoughtful position.
I would also add to the questioner, that it depends on the context of the advice. If the advice was given TO a person who is not a typical specific stock investor, especially in the lower price speculative arena, I think the advice was typical of what is considered good advice in those cases. Even more so if the advice was given BY an advisor that is not particularly learned on .ob equities.
It sounds like the basic investing 101 guideline of ‘don’t bother with penny stocks, they will burn you’.
Like you say, don’t invest more in a more pure speculative play than you can afford to lose.
I must say though, losses can keep adding up over time such that it can get a little depressing.
As far as NNVC goes though, I think it is a very good speculative buy at this point. I think they will have a final product or two to the market someday. But even if that was never to happen, they appear strong enough (good enough science to garnish real investment and grant funds) for at least 3 years of sustainability. During that period, I would expect a news cycle or two to raise it above $3/share as a minimum and thus consider it a strong speculative buy at any price under $1/share. I think like you do though, that it will have final products in the market someday and that is what I am holding for.
Oh, and to Echo, Yes I should write much more to congress, the president and many others.
Wishing all the best of good buys!
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM